Novartis & Roche
11 shared events · Importance 4 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Roche: Roche is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
Novartis: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Roche: One of the nine companies whose chairs signed the letter seeking faster trials, IP protections and fiscal flexibility in Europe. The move highlights its stake in European research and development competitiveness.
Sep 22, 2026 · 6 articles
International
Novartis: Novartis is a key investor, announcing two U.S. projects: a biomedical research center in San Diego and a cancer-drug production facility in Texas.
Roche: Roche is expanding its output in North Carolina as part of the Swiss investment surge.
Jun 07, 2026 · 7 articles
Business
Novartis: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Roche: Roche is referenced as a Swiss rival whose total shareholder returns under the same period were lower than Novartis', providing context for investor patience with management.
Sep 08, 2026 · 21 articles
Business
Novartis: Novartis' pelacarsen trial failed its primary endpoint, a setback for its cardiovascular pipeline.
Roche: Roche is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Sep 04, 2026 · 12 articles
Tech
Novartis: Novartis was an attendee at the summit, suggesting its engagement with digital health technologies for clinical trials.
Roche: Roche was an attendee at the summit, indicating its presence in the digital biomarkers space and potential interest in technologies like 'CART BP pro'.
Jul 03, 2026 · 8 articles
Tech
Novartis: Novartis CEO Shar Narasimhan sits on Anthropic's board, linking the pharma giant to Anthropic's AI drug efforts.
Roche: Parent of F. Hoffmann-La Roche — Genentech, indirectly benefiting from Anthropic's AI services supplied to F. Hoffmann-La Roche — Genentech.
Sep 18, 2026 · 22 articles
Business
Novartis: Novartis is mentioned as a previous employer of Ian Marks, providing context for his experience but not directly affected by the event.
Roche: Roche is mentioned as a previous employer of Ian Marks, providing context for his experience but not directly affected by the event.
Aug 10, 2026 · 6 articles
Business
Novartis: Novartis is among the Swiss pharmaceutical giants that now dwarf LVMH in market value.
Roche: Roche is among the Swiss pharmaceutical giants that now dwarf LVMH in market value.
Sep 15, 2026 · 6 articles
Business
Novartis: Dhavalkumar Patel>>> spent 10 years at Novartis>>> as Head of Research for NIBR Europe.
Roche: Roche>>> acquired Inflazome>>> in 2020.
Jun 12, 2026 · 6 articles
Domestic
Novartis: Novartis>>> shed 0.3%-0.7% in one session but moved up by 1.85% in another, showing mixed performance in the Switzerland>>> market.
Roche: Roche>>> posted modest gains, contributing to the overall positive sentiment in the Switzerland>>> market.
May 21, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Novartis and Roche interact across events, view sentiment trends, and discover connected entities.
Open Dashboard